

Supplementary Table S2. Autoantibodies in PAROKRANK and in the SLE cohort

AutoAb	PAROKRANK (n=1498) n (%) ¹	SLE patients (n=101) n (%)
CCP2 IgG	52 (3.5)	NA
RF	70 (4.7)	28 (27.7)
dsDNA	31 (2.1)	62 (61.4)
Sm	1 (0.0)	21 (20.8)
SmRNP	4 (0.3)	30 (29.7)
SSA Ro52	12 (0.8)	35 (34.7)
SSA Ro60	12 (0.8)	44 (43.6)
SSB	18 (1.2)	24 (23.8)
RNP 68	4 (0.3)	15 (14.9)
B2GP1 IgA	14 (0.9)	13 (12.9)
B2GP1 IgG	48 (3.2)	21 (20.8)
B2GP1 IgM	31 (2.1)	4 (4.0)
CL IgA	14 (0.9)	12 (11.9)
CL IgG	52 (3.5)	20 (19.8)
CL IgM	34 (2.3)	6 (5.9)
ANA	NA	98 (97.0)
Centromere	NA	3 (3.0)
Ribosomal P protein	NA	4 (4.0)
Nucleosome	NA	50 (49.5)

¹ Numbers (n) and frequencies (%) of different autoantibodies are shown. CCP2 = cyclic citrullinated peptide 2, RF = rheumatoid factor, dsDNA = double stranded DNA, Sm = Smith, SmRNP= Smith ribonucleoprotein, SSA = Sjögren's-syndrome-related antigen A, SSB = Sjögren's-syndrome-related antigen B, B2GP1 = β 2-glycoprotein1, CL = cardiolipin, ANA = anti-nuclear antibodies, NA = not analysed.